Themistoklis Vassiliadis

Themistoklis Vassiliadis

Auto-generated profile, based on publicly available information

Themistoklis Vassiliadis

Third Department of Internal Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki, 546 09 Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Metabolism
Verified
Journal Article
Closed access
VAVasilios Athyros
Vasilios Athyros
TATheodore K Alexandrides
Theodore K Alexandrides
HBHelen Bilianou
Helen Bilianou
ECEvangelos Cholongitas
Evangelos Cholongitas
MDMichael Doumas
Michael Doumas
CMChristos Mantzoros
Christos Mantzoros

26 January 2011 in Gut
Verified
Journal Article
Closed access
PDF file
George PapatheodoridisGeorge Papatheodoridis
George Papatheodoridis
SMSpilios Manolakopoulos
Spilios Manolakopoulos
GTGiota Touloumi
Giota Touloumi
GVGeorgia Vourli
Georgia Vourli
MRMaria Raptopoulou-Gigi
Maria Raptopoulou-Gigi
FGfor the HEPNET. Greece Cohort Study Group
for the HEPNET. Greece Cohort Study Group
Objective To evaluate the risk and predictors of hepatocellular carcinoma (HCC) in HBeAg-negative chronic hepatitis B patients of the large HEPNET.Greece cohort study who received long-term oral antivirals starting with lamivudine monotherapy. Design Retrospective analysis of HCC incidence in HBeAg-negative chronic hepatitis B patients from a retrospective–prospective cohort who were treated with nucleos(t)ide analogue(s) starting with lamivudine monotherapy for ≥12 months. Setting A nationwide network of liver centres. Patients 818 patients were included: 517 with chronic hepatitis B only; 160 with compensated cirrhosis; 56 with decompensated cirrhosis; 85 with unclassified disease severity. Interventions All patients were treated with nucleos(t)ide analogue(s) starting with lamivudine monotherapy. Main outcome measures Development of HCC. Results During a median follow-up of 4.7 years, HCC developed in 49 (6.0%) patients. The 5-year cumulative incidence of HCC was higher in patients with cirrhosis than in those with chronic hepatitis B only (11.5% vs 3.2%, respectively; p<0.001). HCC developed in 0.7%, 6.7% and 11.7% of patients 60 years old, respectively (p<0.001). Virological on-therapy remission did not significantly affect the incidence of HCC in all patients or those with cirrhosis, but it showed a trend for lower HCC incidence in patients with chronic hepatitis B only (p=0.076). In multivariate analysis, age, gender and cirrhosis were independently associated with HCC risk regardless of virological remission. Conclusions Long-term therapy with nucleos(t)ide analogue(s) starting with lamivudine monotherapy does not eliminate HCC risk in HBeAg-negative chronic hepatitis B. The risk of HCC is particularly high in patients with cirrhosis, who should remain under HCC surveillance even during effective therapy. Older age and male gender remain independent risk factors for HCC, while virological on-therapy remission does not seem to significantly reduce the overall incidence of HCC.

1 April 2002 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
VAVasilios Athyros
Vasilios Athyros
OGOlga I. Giouleme
Olga I. Giouleme
NNNikolaos L. Nikolaidis
Nikolaos L. Nikolaidis
TVThemistoklis V. Vasiliadis
Themistoklis V. Vasiliadis
VBVassilios I. Bouloukos
Vassilios I. Bouloukos
NENikolaos P. Eugenidis
Nikolaos P. Eugenidis
An acute and potentially life-threatening complication of hypertriglyceridemia (HTG) is acute pancreatitis (AP). Hypertriglyceridemia, usually severe, may be primary in origin or secondary to alcohol abuse, diabetes mellitus, pregnancy, and use of drugs. The efficacy of treatment to prevent relapses in 17 patients with AP attributed to HTG was investigated in the current prospective study. The mean follow-up period of patients was 42 months. Hypertriglyceridemia-induced AP comprised 6.9% of all patients with AP (n = 246) hospitalized in our clinic during the study (6 years). Causative conditions of HTG-induced AP were familial HTG in eight patients, HTG caused by uncontrolled diabetes mellitus in five, HTG aggravated by drugs in two (one by tamoxifen and one by fluvastatin), familial hyperchylomicronemia (HCM) in one, and lipemia of pregnancy in one. During the acute phase of pancreatitis, patients underwent standard treatment. Thereafter, HTG was efficiently controlled with high dosages of fibrates or a fibrate plus acipimox, except for the patient with HCM, who was on a specific diet (the only source of fat was a special oil consisting of medium chain triglyceride) and taking a high dosage of acipimox. One of the patients died during the acute phase of pancreatitis with acute respiratory distress syndrome. During follow-up, maintenance treatment was successful and only one patient relapsed, because he discontinued diet and drug treatment. Appropriate diet and drug treatment, including dose titration, of severe HTG is very effective in preventing relapses of HTG-induced AP.

20 June 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
PKPanagiotis Katsinelos
Panagiotis Katsinelos
SGStergios Gkagkalis
Stergios Gkagkalis
GCGrigorios Chatzimavroudis
Grigorios Chatzimavroudis
ABAthanasios Beltsis
Athanasios Beltsis
STSotiris Terzoudis
Sotiris Terzoudis
JKJannis Kountouras
Jannis Kountouras

15 October 2009 in Rheumatology International
Verified
Journal Article
Closed access
Athina PyrpasopoulouAthina Pyrpasopoulou
Athina Pyrpasopoulou
SDStella Douma
Stella Douma
TVThemistoklis Vassiliadis
Themistoklis Vassiliadis
SCSofia Chatzimichailidou
Sofia Chatzimichailidou
ATAreti Triantafyllou
Areti Triantafyllou
SASpyros Aslanidis
Spyros Aslanidis

1 January 2011 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
VAVasilios Athyros
Vasilios Athyros
OGOlga Giouleme
Olga Giouleme
EGEmmanouel S. Ganotakis
Emmanouel S. Ganotakis
MEMoses Elisaf
Moses Elisaf
KTKonstantinos Tziomalos
Konstantinos Tziomalos
DMDimitri P. Mikhailidis
Dimitri P. Mikhailidis
Introduction : Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome (MetS), is common and accounts for 80% of cases of elevated liver function tests (LFTs). We assessed the long-term effects of multifactorial intervention on LFTs and their association with...